

Insert new claim 34 as follows:

--34~~15~~ A method in accordance with claim 6, wherein said administering step comprises bringing said interferon into contact with the mucosa lining the mouth and/or throat of the mammal being treated.

Delete claims 17-20 and substitute therefor new claims 35-38 as follows:

--35. An interferon composition for oromucosal contact, comprising a stimulating amount of interferon greater than ~~about~~  $20 \times 10^6$  IU, said amount exceeding that amount which would elicit a pathological response when parenterally administered, and a vehicle or excipient which facilitates contact with the mucosa lining the mouth or throat upon administration, said composition being in the form of a lozenge or buccal tablet.

--36. An interferon composition in accordance with claim 35, wherein said stimulating amount of interferon is ~~about~~  $20 \times 10^6$  IU to about  $1000 \times 10^6$  IU.

--37. An interferon composition in accordance with claim 35, wherein said stimulating amount of interferon is ~~about~~  $20 \times 10^6$  to about  $500 \times 10^6$  IU.

--38. An interferon composition in accordance with claim 35, wherein said stimulating amount of interferon is about  $50 \times 10^6$  to about  $500 \times 10^6$  IU.--

#### REMARKS

Claims 6, 13, and 22-38 presently appear in this case. No claims have been allowed. The present amendment is intended to